10:22 AM
 | 
Mar 23, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Portola reports additional Phase IIIb/IV data of Factor Xa inhibitor antidote AndexXa

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) reported data from 228 patients with Factor Xa inhibitor-associated acute major bleeding in the Phase IIIb/IV ANNEXA-4 trial showing that AndexXa andexanet alfa (IndexXa, PRT4445, PRT064445) led to “excellent or good” hemostasis, defined as stoppage of bleeding, within 12 hours of infusion in 83% of patients. Portola reported a thrombotic event rate of 11% and a mortality rate of...

Read the full 294 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >